Abrilada Shortage: What Providers and Prescribers Need to Know in 2026

As a provider prescribing biologic therapies for autoimmune conditions, you've likely encountered patients reporting difficulty filling their Abrilada (Adalimumab-afzb) prescriptions. While Abrilada is not formally in shortage, the realities of specialty pharmacy distribution, PBM formulary decisions, and the competitive adalimumab biosimilar market create meaningful access barriers for patients.

This briefing provides an overview of the current Abrilada landscape, prescribing considerations, and practical tools to help your patients stay on therapy.

Timeline: Abrilada's Market Entry and Evolution

Understanding Abrilada's history helps contextualize its current market position:

• November 2019: FDA approves Abrilada (Adalimumab-afzb) as a biosimilar to Humira, manufactured by Pfizer.
• October 2023: FDA grants Abrilada interchangeable designation for all approved indications.
• Late October 2023: Pfizer launches Abrilada commercially at two WAC price points — one approximately 5% below Humira's list price and another approximately 60% below.
• 2024–2025: The adalimumab biosimilar market matures with ten approved biosimilars, seven of which hold interchangeable designations. PBMs increasingly mandate biosimilar use.
• Early 2026: Biosimilars collectively hold over 50% of the adalimumab market share. Price competition continues to intensify.

Prescribing Implications

Interchangeability and Pharmacy-Level Substitution

Abrilada's interchangeable designation means pharmacists in most states can substitute it for Humira (or vice versa) without prescriber intervention. However, state pharmacy practice acts vary, and some states require prescriber notification. Be aware of your state's specific requirements.

When writing prescriptions, consider:

• Formulary alignment: Prescribing the biosimilar preferred by the patient's PBM can avoid prior authorization delays and improve fill rates.
• DAW codes: If you have a clinical reason to require Abrilada specifically (e.g., patient tolerance of the citrate-free formulation), use a Dispense as Written (DAW) code to prevent substitution.
• Electronic prescribing: Ensure your EHR system lists Abrilada as a selectable product. Some systems may default to brand Humira or a different biosimilar.

Clinical Equivalence Across Biosimilars

All FDA-approved interchangeable adalimumab biosimilars have demonstrated clinical equivalence to the reference product through rigorous analytical, preclinical, and clinical studies including switching studies. There is no clinically meaningful difference in efficacy, safety, or immunogenicity between Abrilada and other interchangeable adalimumab products.

For patients expressing concern about switching, you can reassure them that the FDA's interchangeability standard specifically evaluates switching scenarios and requires that outcomes are indistinguishable from continuous use of the reference product.

Current Availability Picture

Abrilada is not listed on the FDA Drug Shortage Database or ASHP shortage listings. Pfizer continues to manufacture and supply the product. However, effective availability varies based on:

• PBM formulary position: The three largest PBMs (CVS Caremark, Express Scripts, OptumRx) each have preferred biosimilar strategies. Abrilada's formulary position varies by PBM and by individual employer/plan within each PBM.
• Specialty pharmacy network: Abrilada is available through Pfizer's specialty pharmacy distribution network. However, some specialty pharmacies primarily stock the biosimilar(s) preferred by their largest clients.
• Regional variation: Availability can vary by geography based on local PBM contracts and specialty pharmacy coverage areas.

Cost and Access Considerations

Pricing

Abrilada is available at two WAC price points:

• Standard WAC: Approximately 5% below Humira's list price (~$6,700/month)
• Low WAC: Approximately 60% below Humira's list price (~$2,800–$3,200/month)

For context, some competing biosimilars (Hadlima, Simlandi) offer WAC discounts of 85–86% below Humira. This pricing differential affects formulary decisions.

Patient Assistance Resources

For patients facing access or affordability barriers:

• Pfizer enCompass Co-Pay Assistance: Eligible commercially insured patients may pay as little as $0 per dose. Contact: 1-844-722-6672.
• Pfizer RxPathways Patient Assistance: Provides Abrilada at no cost for qualifying uninsured or underinsured patients.
• NeedyMeds and RxAssist: Third-party databases of patient assistance programs.

Tools and Resources for Your Practice

Several resources can help streamline access for your patients:

Medfinder for Providers

Medfinder is a free platform that helps providers and patients check medication availability across pharmacies. You and your staff can use it to quickly identify specialty pharmacies that stock Abrilada or alternative biosimilars.

Pfizer enCompass Provider Portal

The Pfizer enCompass program offers provider-facing support including benefits investigation, prior authorization assistance, and appeals support. This can reduce the administrative burden on your practice when starting patients on Abrilada.

Electronic Prior Authorization (ePA)

If your EHR supports electronic prior authorization, use it. ePA systems can significantly reduce turnaround time compared to fax-based prior auth processes — from days to hours in many cases.

Looking Ahead

The adalimumab biosimilar market is expected to continue evolving in 2026 and beyond:

• Further price compression: As more biosimilars gain interchangeable status and PBM negotiations continue, prices are expected to decline further.
• Formulary consolidation: PBMs are likely to narrow preferred biosimilar lists, which may improve or complicate Abrilada access depending on formulary outcomes.
• Biosimilar adoption mandates: Some state Medicaid programs and employer plans are implementing mandatory biosimilar substitution policies.

Staying current on your patients' formulary requirements and maintaining flexibility in your prescribing approach will be key to ensuring uninterrupted access to adalimumab therapy.

Final Thoughts

Abrilada remains a clinically sound choice for adalimumab therapy, backed by robust biosimilar and interchangeability data. The primary access barriers are administrative and market-driven, not supply-related. By aligning prescriptions with formulary preferences, leveraging manufacturer support programs, and using tools like Medfinder, you can help your patients maintain consistent access to treatment.

For related resources, see our provider guides on helping patients find Abrilada in stock and helping patients save money on Abrilada.